Pause in AstraZeneca vaccine trial not necessarily a setback, says UK health minister

AstraZeneca Plc said it had paused global trials, including large late-stage trials, of its experimental coronavirus vaccine due to an unexplained illness in a study participant.

Safety issue with Oxford-AstraZeneca vaccine trial; will this delay launch?
LONDON: Britain's Health Secretary Matt Hancock said on Wednesday that AstraZeneca's decision to pause its coronavirus vaccine trials was a challenge but would not necessarily set back efforts to develop a vaccine.

AstraZeneca Plc said it had paused global trials, including large late-stage trials, of its experimental coronavirus vaccine due to an unexplained illness in a study participant.

"It is obviously a challenge to this particular vaccine trial," Hancock said on Sky News when asked about the pause in the trial. "It's not actually the first time this has happened to the Oxford vaccine."


Asked whether it would set back the vaccine development process, he said: "Not necessarily, it depends on what they find when they do the investigation."
Download
The Economic Times Business News App
for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App
for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

Related Companies

More from our Partners

Loading next story
Business News › News › International › Business › Pause in AstraZeneca vaccine trial not necessarily a setback, says UK health minister
Text Size:AAA
Success
This article has been saved

*

+